Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Forensic, investigative and diagnostic microbiology: similar technologies but different priorities.

Blondeau LD, Rubin JE, Deneer H, Kanthan R, Sanche S, Hamula C, Blondeau JM.

Future Microbiol. 2019 May;14:553-558. doi: 10.2217/fmb-2019-0088. Epub 2019 May 31. No abstract available.

2.

The in vitro antibacterial activity of the anthelmintic drug oxyclozanide against common small animal bacterial pathogens.

Levinson MR, Blondeau JM, Rosenkrantz WS, Plowgian CB.

Vet Dermatol. 2019 Aug;30(4):314-e87. doi: 10.1111/vde.12755. Epub 2019 May 7.

PMID:
31062461
4.

Tetrasodium EDTA Is Effective at Eradicating Biofilms Formed by Clinically Relevant Microorganisms from Patients' Central Venous Catheters.

Liu F, Hansra S, Crockford G, Köster W, Allan BJ, Blondeau JM, Lainesse C, White AP.

mSphere. 2018 Nov 28;3(6). pii: e00525-18. doi: 10.1128/mSphere.00525-18.

5.

The 24-h clinical microbiology service is essential for patient management.

Blondeau JM, Idelevich EA.

Future Microbiol. 2018 Nov;13:1625-1628. doi: 10.2217/fmb-2018-0228. Epub 2018 Nov 14. No abstract available.

6.

Epidemiology of bacterial corneal ulcers at tertiary centres in Vancouver, B.C.

Termote K, Joe AW, Butler AL, McCarthy M, Blondeau JM, Iovieno A, Holland SP, Yeung SN.

Can J Ophthalmol. 2018 Aug;53(4):330-336. doi: 10.1016/j.jcjo.2017.11.001. Epub 2018 Feb 3.

PMID:
30119785
7.

A pilot study investigating the in vitro efficacy of sucralfate against common veterinary cutaneous pathogens.

Yen T, Boord MJ, Ghubash R, Blondeau JM.

J Small Anim Pract. 2018 Nov;59(11):691-694. doi: 10.1111/jsap.12902. Epub 2018 Jul 4.

PMID:
29972242
8.

Targeted drug delivery and drug resistant pathogens.

Blondeau JM.

Expert Rev Respir Med. 2018 Mar;12(3):161-164. doi: 10.1080/17476348.2018.1420479. Epub 2017 Dec 26. No abstract available.

PMID:
29265893
9.

Antimicrobial resistance & 'Man's best friend': what they give to us we might be giving right back.

Blondeau JM.

Future Microbiol. 2017 Jun;12:549-553. doi: 10.2217/fmb-2017-0043. Epub 2017 Jun 12. No abstract available.

10.

Comparative in vitro killing of canine strains of Staphylococcus pseudintermedius and Escherichia coli by cefovecin, cefazolin, doxycycline and pradofloxacin.

Blondeau JM, Shebelski SD.

Vet Dermatol. 2016 Aug;27(4):267-e63. doi: 10.1111/vde.12334. Epub 2016 Jun 15.

PMID:
27307405
11.
12.

Antibiotic resistance in hospitals.

Alsaeed A, Blondeau JM.

Future Microbiol. 2015;10(3):303-7. doi: 10.2217/fmb.15.10. No abstract available.

PMID:
25812451
13.

Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations.

Blondeau JM, Shebelski SD, Hesje CK.

Int J Antimicrob Agents. 2015 Jun;45(6):594-9. doi: 10.1016/j.ijantimicag.2014.12.034. Epub 2015 Feb 16.

PMID:
25752567
14.

Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.

Hesje CK, Drlica K, Blondeau JM.

J Antimicrob Chemother. 2015 Feb;70(2):494-7. doi: 10.1093/jac/dku389. Epub 2014 Oct 16.

15.

Response to letter from J Mottet "Comments on the ISCAID Guidelines on the use of antimicrobial therapies in canine superficial bacterial folliculitis".

Lloyd DH, Weese JS, Blondeau JM, Boothe D, Breitschwerdt E, Guardabassi L, Papich MG, Rankin S, Turnidge JD, Sykes JE.

Vet Dermatol. 2014 Dec;25(6):567-8. doi: 10.1111/vde.12167. Epub 2014 Aug 11. No abstract available.

PMID:
25109890
16.

Pradofloxacin: a novel veterinary fluoroquinolone for treatment of bacterial infections in cats.

Sykes JE, Blondeau JM.

Vet J. 2014 Aug;201(2):207-14. doi: 10.1016/j.tvjl.2014.06.008. Epub 2014 Jun 10. Review.

PMID:
24997792
17.

Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases).

Hillier A, Lloyd DH, Weese JS, Blondeau JM, Boothe D, Breitschwerdt E, Guardabassi L, Papich MG, Rankin S, Turnidge JD, Sykes JE.

Vet Dermatol. 2014 Jun;25(3):163-e43. doi: 10.1111/vde.12118. Epub 2014 Apr 11. Review.

18.

Gram-negative superbugs: inappropriate antimicrobial therapy and mortality.

Blondeau J.

Expert Rev Clin Pharmacol. 2013 Jul;6(4):347-9. doi: 10.1586/17512433.2013.811831. No abstract available.

PMID:
23927660
19.

Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11.

Lagacé-Wiens PR, Adam HJ, Low DE, Blondeau JM, Baxter MR, Denisuik AJ, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i23-9. doi: 10.1093/jac/dkt023.

PMID:
23587775
20.

Quinolones and where they fit in today's environment of multidrug-resistant bugs.

Blondeau JM, Farshad S.

Expert Rev Clin Pharmacol. 2012 Nov;5(6):609-11. doi: 10.1586/ecp.12.61. No abstract available.

PMID:
23234320
21.

Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.

Metzler K, Drlica K, Blondeau JM.

J Antimicrob Chemother. 2013 Mar;68(3):631-5. doi: 10.1093/jac/dks461. Epub 2012 Nov 20.

22.

Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica.

Blondeau JM, Borsos S, Blondeau LD, Blondeau BJ, Hesje CE.

Vet Microbiol. 2012 Nov 9;160(1-2):85-90. doi: 10.1016/j.vetmic.2012.05.006. Epub 2012 May 15.

PMID:
22677482
23.

Macrocyclic antibiotics: a novel class of drug for the treatment of Clostridium difficile infection.

Blondeau JM.

Expert Rev Clin Pharmacol. 2012 Jan;5(1):9-11. doi: 10.1586/ecp.11.71. No abstract available.

PMID:
22142153
24.
25.

Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases.

Weese JS, Blondeau JM, Boothe D, Breitschwerdt EB, Guardabassi L, Hillier A, Lloyd DH, Papich MG, Rankin SC, Turnidge JD, Sykes JE.

Vet Med Int. 2011;2011:263768. doi: 10.4061/2011/263768. Epub 2011 Jun 27.

26.

Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones.

McDonald M, Blondeau JM.

J Cataract Refract Surg. 2010 Sep;36(9):1588-98. doi: 10.1016/j.jcrs.2010.06.028. Review.

PMID:
20692574
27.

New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.

Blondeau JM.

Vet Dermatol. 2009 Oct;20(5-6):383-96. doi: 10.1111/j.1365-3164.2009.00856.x.

PMID:
20178475
28.

[Gemifloxacin for the treatment of uncomplicated urinary infections (acute cystitis)].

Blondeau JM, Tillotson GS.

Ginecol Obstet Mex. 2009 Dec;77(12):573-82. Review. Spanish.

PMID:
20077882
29.

Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.

Hesje CK, Borsos SD, Blondeau JM.

J Ocul Pharmacol Ther. 2009 Aug;25(4):329-34. doi: 10.1089/jop.2009.0031.

PMID:
19650708
30.

What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?

Blondeau JM.

J Antimicrob Chemother. 2009 Feb;63(2):238-42. doi: 10.1093/jac/dkn477. Epub 2008 Nov 20. Review.

PMID:
19028718
31.

Capnocytophaga spp. DF-1 pneumonia in an immune-competent 56-year old man post-CABG.

Wilde B, Angel SF, Blondeau JM.

J Chemother. 2008 Feb;20(1):126-9. Review.

PMID:
18343755
32.

Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.

Blondeau JM, Tillotson G.

Int J Antimicrob Agents. 2008 Apr;31(4):299-306. doi: 10.1016/j.ijantimicag.2007.12.003. Epub 2008 Feb 13. Review.

PMID:
18276120
33.

MICs, MPCs and PK/PDs: a match (sometimes) made in hosts.

Hesje CK, Tillotson GS, Blondeau JM.

Expert Rev Respir Med. 2007 Aug;1(1):7-16. doi: 10.1586/17476348.1.1.7. No abstract available.

PMID:
20477259
36.

Geminofloxacin for the management of community-acquired respiratory tract infections.

Blondeau JM, Tillotson G, Deangelis J.

J Chemother. 2006 Dec;18(6):582-8. Review.

PMID:
17267335
37.

Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?

Tillotson GS, Blondeau JM, Carroll J.

Expert Rev Anti Infect Ther. 2007 Feb;5(1):53-9. Review.

PMID:
17266453
38.

Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.

Blondeau JM, Blondeau LD, Hesje C, Borsos S.

J Chemother. 2006 Aug;18(4):366-72.

PMID:
17024791
39.

Antimicrobial development and the risk-benefit assessment: recent adverse events and their implications.

Tillotson GS, Blondeau JM.

Expert Rev Anti Infect Ther. 2006 Aug;4(4):515-7. No abstract available.

PMID:
17009930
40.

Optimal antimicrobial therapy: the balance of potency and exposure.

Tillotson GS, Doern GV, Blondeau JM.

Expert Opin Investig Drugs. 2006 Apr;15(4):335-7.

PMID:
16548783
41.

Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.

Hansen GT, Zhao X, Drlica K, Blondeau JM.

Int J Antimicrob Agents. 2006 Feb;27(2):120-4. Epub 2006 Jan 19.

PMID:
16426820
42.

Low correlation between MIC and mutant prevention concentration.

Drlica K, Zhao X, Blondeau JM, Hesje C.

Antimicrob Agents Chemother. 2006 Jan;50(1):403-4. No abstract available.

44.

The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration.

Blondeau JM, Hansen G, Metzler K, Hedlin P.

J Chemother. 2004 Jun;16 Suppl 3:1-19. Review.

PMID:
15334827
45.
46.

Gemifloxacin: a new fluoroquinolone.

Blondeau JM, Missaghi B.

Expert Opin Pharmacother. 2004 May;5(5):1117-52.

PMID:
15155113
47.

Fluoroquinolones: mechanism of action, classification, and development of resistance.

Blondeau JM.

Surv Ophthalmol. 2004 Mar;49 Suppl 2:S73-8. Review.

PMID:
15028482
49.

An outbreak of trichinellosis due to consumption of bear meat infected with Trichinella nativa, in 2 northern Saskatchewan communities.

Schellenberg RS, Tan BJ, Irvine JD, Stockdale DR, Gajadhar AA, Serhir B, Botha J, Armstrong CA, Woods SA, Blondeau JM, McNab TL.

J Infect Dis. 2003 Sep 15;188(6):835-43. Epub 2003 Sep 9.

PMID:
12964114
50.

In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.

Blondeau JM, Hansen G, Metzler KL, Borsos S, Irvine LB, Blanco L.

Int J Antimicrob Agents. 2003 Aug;22(2):147-54.

PMID:
12927955

Supplemental Content

Loading ...
Support Center